Last week in GLP1 (2025/09/15)

GLP1.Guide Staff

14 Sep 2025 — 1 min read

Here’s what happened last week in the GLP1 ecosystem:

🧑‍⚖️ Lawsuits over the negative side effects of GLP1s

🌐 The WHO is building a guideline for GLP1 use and requesting comments

🎭 Celebrity endorsements continue: Andy Cohen reveals use of GLP1s for weight management

🚨 GLP1 is now being used in SMS scams

📰 More anecdotal evidence of people not staying on GLP1s for over a year

Go deeper, learn more

Here are our latest deep dives on the recent news and research behind GLP1s:

Here’s what happened last week in the GLP1 ecosystem: 📊 Study: Wegovy pill shows 16.6% weight loss 📢 Eli Lilly says Orforglipron is even better than the Wegovy pill 📺 GLP1s in patch form? Not yet 📑 GLP1s could reduce all-cause mortality by up to 6% by 2045 ❓Bariatric surgery more effective

A new study on GLP1s eye risk

One of the biggest emerging risks of using GLP1s has been the link between GLP1s and vision loss — whether via NAION or macular degeneration. We’ve covered this before: The link between Semaglutide & vision loss (NAION)How deep is the link between GLP1s and possible vision loss? We examine

Massive GLP1 use in Silicon Valley survey

We mostly hear of increased adoption of GLP1s in the mainstream — entertainers and public figures being quizzed on whether they use it or not, spectacular transformations for patients who have found a GLP1 that works for them, etc. Silicon Valley and those that like to experiment or “bio-hack” were very

An under-reported negative side effect: CVS

Keeping track of negative side effects of GLP1s is just as important (if not more important) than keeping track of positive side effects. Cyclic Vomiting Syndrome is a *rare* negative side effect that doesn’t come up in the research very often, but after hearing anecdotal reports of this side